- Home
- ARHS vs NRIX Comparison
ARHS vs NRIX Comparison
Compare ARHS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | NRIX |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARHS | NRIX |
|---|---|---|
| Price | $11.73 | $19.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $11.81 | ★ $27.46 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,361,388,000.00 | $83,687,000.00 |
| Revenue This Year | $9.59 | $59.40 |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $22.56 | ★ N/A |
| Revenue Growth | 7.36 | ★ 48.32 |
| 52 Week Low | $6.61 | $8.18 |
| 52 Week High | $13.02 | $22.50 |
Technical Indicators
Market Signals| Indicator | ARHS | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 63.80 |
| Support Level | $11.30 | $17.44 |
| Resistance Level | $11.89 | $19.67 |
| Average True Range (ATR) | 0.48 | 1.14 |
| MACD | 0.08 | -0.20 |
| Stochastic Oscillator | 72.35 | 37.95 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.